Clinical trial
Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic…
NCT00191438 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191438 |
|---|---|
| Title | Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents |
| Official title | Phase III Study of Docetaxel in Combination With Gemcitabine Versus Docetaxel in Combination With Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | gemcitabine, capecitabine, docetaxel |
| Enrollment | 300 |
| Start date | Oct 1, 2002 |
| Completion | Mar 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | May 28, 2007 |
| Countries | France, Germany, Italy, Netherlands, Spain, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: